Celldex Therapeutics (CLDX) reported quarterly earnings results on Thursday, May-5-2016. The company reported $-0.35 EPS for the quarter. Analysts had a consensus estimate of $-0.35. The company posted revenue of $1.30 million in the period, compared to analysts expectations of $1.06 million. The company’s revenue was up 160.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.33 EPS.
Many Wall Street Analysts have commented on Celldex Therapeutics. Celldex Therapeutics was Downgraded by Jefferies to ” Hold” on Mar 8, 2016. Celldex Therapeutics was Downgraded by Guggenheim to ” Neutral” on Mar 7, 2016. Wedbush Downgraded Celldex Therapeutics on Mar 7, 2016 to ” Neutral”, Price Target of the shares are set at $4.
Celldex Therapeutics closed down -0.24 points or -5.90% at $3.83 with 36,84,189 shares getting traded on Wednesday. Post opening the session at $4.08, the shares hit an intraday low of $3.82 and an intraday high of $4.21 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
In a different news, on Nov 25, 2015, Avery W Catlin (Sr. VP & CFO) sold 25,000 shares at $18.00 per share price. According to the SEC, on Aug 26, 2015, Larry Ellberger (director) purchased 5,000 shares at $14.00 per share price. On Aug 14, 2015, Anthony S Marucci (CEO) purchased 5,800 shares at $16.81 per share price, according to the Form-4 filing with the securities and exchange commission.
Celldex Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development includes varlilumab also referred to as CDX-1127 a fully human therapeutic monoclonal antibody for cancer indications CDX-1401 a targeted immunotherapeutic for cancer indications and CDX-301 an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.